Maravai LifeSciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Maravai LifeSciences (MRVI).

Price Target Range — 11 Quarters

Analyst Consensus — 9 Analysts

5Buy

3Hold

1Sell

Consensus RatingBuy# Analysts9Avg. Consensus PT$6Upside to Avg. PT-22.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 9, 2026	UBS	Dan Brennan	PT Raise	Neutral	$3→$8
Aug 7, 2026	Wells Fargo	Evan Stampler	PT Raise	Overweight	$6→$7
May 8, 2026	Wells Fargo	Brandon Couillard	PT Raise	Overweight	$5→$6
Dec 15, 2025	Wells Fargo	Brandon Couillard	PT Raise	Overweight	$4→$5
Aug 12, 2025	Craig-Hallum	Christian Schwab	PT Cut	Buy	$10→$5
Aug 12, 2025	RBC Capital	Conor McNamara	PT Cut	Outperform	$7→$5
May 13, 2025	Craig-Hallum	Christian Schwab	PT Cut	Buy	$12→$10
May 13, 2025	Baird	Catherine Schulte	PT Cut	Neutral	$3→$2
Mar 25, 2025	Morgan Stanley	Tejas Savant	PT Cut	Equal-Weight	$7→$5
Mar 21, 2025	UBS	Dan Brennan	PT Cut	Neutral	$8→$3
Mar 3, 2025	B of A Securities	Michael Ryskin	PT Cut	Buy	$9→$8
Feb 26, 2025	Baird	Catherine Schulte	Downgrade	Outperform→Neutral	$9→$3
Dec 5, 2024	Goldman Sachs	Matthew Sykes	Downgrade	Neutral→Sell	$7→$4
Nov 14, 2024	Wolfe Research	Doug Schenkel	Initiate	Peer Perform	—
Nov 8, 2024	RBC Capital	Conor McNamara	PT Cut	Outperform	$17→$13
Nov 8, 2024	William Blair	Matt Larew	Downgrade	Outperform→Market Perform	—
Nov 8, 2024	Baird	Catherine Schulte	PT Cut	Outperform	$10→$9
Oct 8, 2024	Goldman Sachs	Matthew Sykes	PT Cut	Neutral	$8→$7
Aug 27, 2024	Wells Fargo	Brandon Couillard	Initiate	Overweight	$10
Aug 16, 2024	RBC Capital	Conor McNamara	Maintained	Outperform	$15

Analyst Ratings News

PRO
UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

UBS analyst Dan Brennan maintains Maravai LifeSciences (NASDAQ:MRVI) with a Neutral and raises the price target from $2.5 to $8.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

Wells Fargo analyst Evan Stampler maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and raises the price target from $5.5 to $6.5.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5

Wells Fargo analyst Brandon Couillard maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and raises the price target from $4.5 to $5.5.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $4.5

Wells Fargo analyst Brandon Couillard maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and raises the price target from $4 to $4.5.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $5

RBC Capital analyst Conor McNamara maintains Maravai LifeSciences (NASDAQ:MRVI) with a Outperform and lowers the price target from $7 to $5.

Benzinga Newsdesk

These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results

Avi Kapoor

Maravai LifeSciences Holdings Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Maravai LifeSciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $4.5

PRO
RBC Capital Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $5

These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results

People Also Watch

People Also Watch

Maravai LifeSciences Holdings Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Maravai LifeSciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

PROWells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

PROWells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5

PROWells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $4.5

PRORBC Capital Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $5

These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results

People Also Watch

People Also Watch

PRO
UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $4.5

PRO
RBC Capital Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $5